Advertisement

Volume 129, Issue 25

Cover Figure: Cytospin preparation after 7-day culture of the novel human megakaryocyte progenitor (MegP) in liquid medium (May-Giemsa staining). See the article by Miyawaki et al.

WASHINGTON, June 22, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Gardner and colleagues report encouraging results of a phase 1 trial with 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL). Their study found a remarkably high minimal residual disease–negative complete remission rate after treatment with a uniquely formulated chimeric antigen receptor (CAR) T-cell product of defined CD4/CD8 composition genetically modified with a CD19-specific 4-1BB:ζ CAR lentiviral vector.

Identification of unipotent megakaryocyte progenitors in human hematopoiesis
Miyawaki et al identify a primitive unipotent progenitor cell population that generates megakaryocytes and platelets in adult humans. They show that it is expanded in myeloproliferative neoplasms, including essential thrombocythemia.

Clinical significance of somatic mutation in unexplained blood cytopenia
Malcovati et al show that somatic gene mutations can identify patients with unexplained cytopenias who have, or are at high risk of developing, myeloid malignancies.

How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy
This How I Treat article written by an internationally known expert discusses the clinical management of recurrent thromboembolism in patients on anticoagulant therapy, a vexing clinical problem and a controversial subject in the field of thrombosis management.

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
This is the first detailed study defining clinical markers associated with venetoclax treatment failure in chronic lymphocytic leukemia (CLL).

EPCR expression marks UM171-expanded CD34+ cord blood stem cells
In careful limiting-dilution and secondary transplantation experiments, Fares et al demonstrate that endothelial protein C receptor (EPCR) is a faithful marker for expansion of human cord blood hematopoietic stem cells in vitro.

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group
This study defines a protocol for the identification of kinase-driven high-risk features, known as a “Ph-like” expression profile, in patients with B-ALL.

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial
and
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial
A large multicenter study report demonstrates that reduction of treatment intensity for acute myeloid leukemia (AML) in children with Down syndrome is feasible without compromising survival and identifies new independent prognostic markers useful for risk-directed therapy. Another paper reports a multicenter trial that evaluates earlier introduction of high-dose cytarabine and a reduced cumulative dose of etoposide. The latter paper reports excellent outcomes for Down syndrome–associated AML and also shows that early flow assessment of minimal residual disease identifies a subgroup of patients at higher risk for relapse.

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.